Cargando…
Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
Itraconazole (ICZ) is a broad spectrum antifungal drug, but used as second or third line therapy due to its low and erratic oral bioavailability. This work was carried out to prepare and characterize matrix type lipid-polymer hybrid nanoparticles (LPHNPs) for dissolution enhancement of ICZ. LPHNPs w...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010992/ https://www.ncbi.nlm.nih.gov/pubmed/36925532 http://dx.doi.org/10.1016/j.heliyon.2023.e14281 |
_version_ | 1784906289784029184 |
---|---|
author | Yousaf, Rimsha Khan, Muhammad Imran Akhtar, Muhammad Furqan Madni, Asadullah Sohail, Muhammad Farhan Saleem, Ammara Irshad, Kanwal Sharif, Ali Rana, Maria |
author_facet | Yousaf, Rimsha Khan, Muhammad Imran Akhtar, Muhammad Furqan Madni, Asadullah Sohail, Muhammad Farhan Saleem, Ammara Irshad, Kanwal Sharif, Ali Rana, Maria |
author_sort | Yousaf, Rimsha |
collection | PubMed |
description | Itraconazole (ICZ) is a broad spectrum antifungal drug, but used as second or third line therapy due to its low and erratic oral bioavailability. This work was carried out to prepare and characterize matrix type lipid-polymer hybrid nanoparticles (LPHNPs) for dissolution enhancement of ICZ. LPHNPs were prepared using solvent diffusion/emulsification technique. Matrix LPHNPs were composed of chitosan (polymer), glyceryl monostearate (lipid) and poloxamer 188 (stabilizer). LPHNPs loaded with ICZ (LPHNPs-1, LPHNPs-2, LPHNPs-3 and LPHNPs-4) were developed using varying concentration of chitosan whereas LPHNPs (LPHNPs-5, LPHNPs-6, LPHNPs-7 and LPHNPs-8) were prepared using varying concentrations of poloxamer 188. LPHNPs loaded with ICZ were further evaluated for entrapment efficiency, particle size, polydispersity index (PDI), zeta potential and dissolution profiles at biorelevant pH conditions. The particle size (LPHNPs-1 to LPHNPs-4) was found to be in range of 421–588 nm with PDI values 0.34–0.41. The particles size of LPHNPs-5 to LPHNPs-8 was found to be in range of 489–725 nm with PDI 0.34–0.74. The entrapment efficiency of LPHNPs-1 to LPHNPs-4 was found to be in range of 85.21%–91.34%. The entrapment efficiency of LPHNPs-5 to LPHNPs-8 was found to be in range 78.32%–90.44%. . The scanning electron microscopy of optimized formulations LPHNPs-1 and LPHNPs-5 indicated formation of oval shaped nanoparticles. DSC thermogram of ICZ loaded LPHNPs also depicted the conversion of crystalline form of ICZ into amorphous form demonstrating the internalization and dissolution enhancement of drug in the hybrid matrix. The cumulative drug dissolved at acidic pH 1.2 was found to be 23.3% and 19.8% for LPHNPs-1 and LPHNPs-5 respectively. Similarly at basic pH values 7.4, cumulative amount of drug dissolved was 90.2% and 83.4% for LPHNPs-1 and LPHNPs-5 respectively. Drug dissolution kinetics exhibited fickian diffusion best described by Korse-meyer Peppas model. The results suggested that chitosan and glyceryl monostearate based matrix LPHNPs could be used as promising approach for dissolution enhancement of ICZ which could further increase its bioavailability. |
format | Online Article Text |
id | pubmed-10010992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100109922023-03-15 Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole Yousaf, Rimsha Khan, Muhammad Imran Akhtar, Muhammad Furqan Madni, Asadullah Sohail, Muhammad Farhan Saleem, Ammara Irshad, Kanwal Sharif, Ali Rana, Maria Heliyon Research Article Itraconazole (ICZ) is a broad spectrum antifungal drug, but used as second or third line therapy due to its low and erratic oral bioavailability. This work was carried out to prepare and characterize matrix type lipid-polymer hybrid nanoparticles (LPHNPs) for dissolution enhancement of ICZ. LPHNPs were prepared using solvent diffusion/emulsification technique. Matrix LPHNPs were composed of chitosan (polymer), glyceryl monostearate (lipid) and poloxamer 188 (stabilizer). LPHNPs loaded with ICZ (LPHNPs-1, LPHNPs-2, LPHNPs-3 and LPHNPs-4) were developed using varying concentration of chitosan whereas LPHNPs (LPHNPs-5, LPHNPs-6, LPHNPs-7 and LPHNPs-8) were prepared using varying concentrations of poloxamer 188. LPHNPs loaded with ICZ were further evaluated for entrapment efficiency, particle size, polydispersity index (PDI), zeta potential and dissolution profiles at biorelevant pH conditions. The particle size (LPHNPs-1 to LPHNPs-4) was found to be in range of 421–588 nm with PDI values 0.34–0.41. The particles size of LPHNPs-5 to LPHNPs-8 was found to be in range of 489–725 nm with PDI 0.34–0.74. The entrapment efficiency of LPHNPs-1 to LPHNPs-4 was found to be in range of 85.21%–91.34%. The entrapment efficiency of LPHNPs-5 to LPHNPs-8 was found to be in range 78.32%–90.44%. . The scanning electron microscopy of optimized formulations LPHNPs-1 and LPHNPs-5 indicated formation of oval shaped nanoparticles. DSC thermogram of ICZ loaded LPHNPs also depicted the conversion of crystalline form of ICZ into amorphous form demonstrating the internalization and dissolution enhancement of drug in the hybrid matrix. The cumulative drug dissolved at acidic pH 1.2 was found to be 23.3% and 19.8% for LPHNPs-1 and LPHNPs-5 respectively. Similarly at basic pH values 7.4, cumulative amount of drug dissolved was 90.2% and 83.4% for LPHNPs-1 and LPHNPs-5 respectively. Drug dissolution kinetics exhibited fickian diffusion best described by Korse-meyer Peppas model. The results suggested that chitosan and glyceryl monostearate based matrix LPHNPs could be used as promising approach for dissolution enhancement of ICZ which could further increase its bioavailability. Elsevier 2023-03-09 /pmc/articles/PMC10010992/ /pubmed/36925532 http://dx.doi.org/10.1016/j.heliyon.2023.e14281 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Yousaf, Rimsha Khan, Muhammad Imran Akhtar, Muhammad Furqan Madni, Asadullah Sohail, Muhammad Farhan Saleem, Ammara Irshad, Kanwal Sharif, Ali Rana, Maria Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole |
title | Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole |
title_full | Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole |
title_fullStr | Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole |
title_full_unstemmed | Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole |
title_short | Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole |
title_sort | development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (lphnps) for oral delivery of itraconazole |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010992/ https://www.ncbi.nlm.nih.gov/pubmed/36925532 http://dx.doi.org/10.1016/j.heliyon.2023.e14281 |
work_keys_str_mv | AT yousafrimsha developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT khanmuhammadimran developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT akhtarmuhammadfurqan developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT madniasadullah developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT sohailmuhammadfarhan developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT saleemammara developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT irshadkanwal developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT sharifali developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole AT ranamaria developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole |